Armata Pharmaceuticals
ARMP
12 hedge funds and large institutions have $475K invested in Armata Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 13 closing their positions.
1.19% more ownership
Funds ownership: 0% → 1.19% (+1.2%)
0% more capital invested
Capital invested by funds: $473K → $475K (+$2K)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
52% less funds holding
Funds holding: 25 → 12 (-13)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$113K |
| 2 |
BlackRock
New York
|
+$43.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.1K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$1.99K |
| 5 |
Morgan Stanley
New York
|
+$276 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$32K |
| 2 |
VF
Virtu Financial
New York
|
-$31K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$21K |
| 4 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
-$18K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$15K |
ARMP Hedge Fund Activity: Q2 2019 in Review
12 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2019, worth a combined $475K — up 0.42% from $473K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ARMP and 1 opened new positions — a net loss of 12 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $113K. The largest seller was Stifel Financial, exiting entirely with an estimated $32K sold.
- 12 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2019, down from 25 in Q1 2019.
- Funds reported $475K of Armata Pharmaceuticals stock for Q2 2019, up 0.42% quarter-over-quarter.
- 1 fund opened new Armata Pharmaceuticals positions in Q2 2019 and 13 closed out, a net change of -12 holders.
- The largest Armata Pharmaceuticals buyer in Q2 2019 was Renaissance Technologies, an estimated $113K added.
- The largest Armata Pharmaceuticals seller in Q2 2019 was Stifel Financial, an estimated $32K sold.
Based on aggregated 13F filings for Q2 2019.